Literature DB >> 12084467

Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.

Ian H Gilbert1.   

Abstract

The protozoan diseases leishmaniasis, Chagas' disease and African trypanosomiasis are major health problems in many countries, particularly developing countries, and there are few drugs available to treat these diseases. Dihydrofolate reductase (DHFR) inhibitors have been used successfully in the treatment of a number of other diseases such as cancer, malaria and bacterial infections; however they have not been used for the treatment of these diseases. This article summarises studies on leishmanial and trypanosomal DHFR inhibitor development and evaluation. Possible mechanisms of resistance to DHFR inhibitors are also discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084467     DOI: 10.1016/s0925-4439(02)00088-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

Review 1.  Target assessment for antiparasitic drug discovery.

Authors:  Julie A Frearson; Paul G Wyatt; Ian H Gilbert; Alan H Fairlamb
Journal:  Trends Parasitol       Date:  2007-10-24

2.  Substrate channeling between the human dihydrofolate reductase and thymidylate synthase.

Authors:  Nuo Wang; J Andrew McCammon
Journal:  Protein Sci       Date:  2015-06-29       Impact factor: 6.725

3.  Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.

Authors:  Olga Senkovich; Vandanajay Bhatia; Nisha Garg; Debasish Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.

Authors:  Rajalakshmi Rajasekaran; Yi-Ping Phoebe Chen
Journal:  J Mol Model       Date:  2012-04-15       Impact factor: 1.810

5.  Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis.

Authors:  Partha Palit; Abhijit Hazra; Arindam Maity; R S K Vijayan; Prabu Manoharan; Sukdeb Banerjee; Nirup B Mondal; Nanda Ghoshal; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

6.  Structure-activity relationship and comparative docking studies for cycloguanil analogs as PfDHFR-TS inhibitors.

Authors:  Prasanna Sivaprakasam; Perrer N Tosso; Robert J Doerksen
Journal:  J Chem Inf Model       Date:  2009-07       Impact factor: 4.956

Review 7.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Authors:  Lucio H Freitas-Junior; Eric Chatelain; Helena Andrade Kim; Jair L Siqueira-Neto
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-28       Impact factor: 4.077

8.  Synthesis, antimicrobial evaluation and docking studies of some novel quinazolinone Schiff base derivatives.

Authors:  Rezvan Rezaee Nasab; Mahboubeh Mansourian; Farshid Hassanzadeh
Journal:  Res Pharm Sci       Date:  2018-06

9.  Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.

Authors:  Kurt S Van Horn; Xiaohua Zhu; Trupti Pandharkar; Sihyung Yang; Brian Vesely; Manu Vanaerschot; Jean-Claude Dujardin; Suman Rijal; Dennis E Kyle; Michael Zhuo Wang; Karl A Werbovetz; Roman Manetsch
Journal:  J Med Chem       Date:  2014-06-17       Impact factor: 7.446

10.  Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives.

Authors:  Rezvan Rezaee Nasab; Farshid Hassanzadeh; Ghadam Ali Khodarahmi; Mahboubeh Rostami; Mahmoud Mirzaei; Ali Jahanian-Najafabadi; Mahboubeh Mansourian
Journal:  Res Pharm Sci       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.